← board
ODTX
Odyssey Therapeuticsdistress 3/10 · well-funded / low risk$18.91+2%today-1% from 52w high
Immunology / Inflammation 1
Lead: ulcerative colitis · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$176M
Runway
1.1 yrs
Shares 1y
—
Price & events
+15.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.6%
1D
+10.8%
1W
+1.9%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
+15.2%
All
Overview
- Market Cap
- $908.27M
- Volume
- 9.93K
- 52 Week Range
- $15.56 – $19.07
- Total Shares
- 48.03M
- Float Shares
- 25.89M
- Short %
- 4.27%
- % Held by Insiders
- 1.93%
- % Held by Institutions
- 47.88%
- RVOL
- 0.03x
Pipeline stages · 1 programs
OD-07656, Vedolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04 | Phase 2 | OD-07656, Vedolizumab | Ulcerative Colitis (UC), UC - Ulcerative Colitis | 57 | recruiting |
Catalyst news & presentations · 6
- 2H 2027Guided 55%readoutPhase 2OD-001 · Phase 2b monotherapy readoutSEC 8-K
- 1H 2027Guided 55%trial initiationsecondaryPhase 1/2OD-002 · Phase 1/2 initiationSEC 8-K
- 2H 2026Guided 55%readoutPhase 2OD-001 · Phase 2a monotherapy data updateSEC 8-K
- 2H 2026Guided 55%trial initiationsecondaryPhase 2OD-001 · Initiation of Phase 2a combination trial with vedolizumab and rinvoqSEC 8-K
- 2H 2026Guided 55%regulatory submissionFiled (NDA/BLA)OD-002 · CTA filingSEC 8-K
- 2026-08-07Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $32 (+69% upside) · 3 analysts
- 2026-06-18OppenheimerOutperform
- 2026-06-02Cantor FitzgeraldOverweight
- 2026-06-02TD CowenBuy
- 2026-06-02WedbushOutperform
- 2026-06-02JP MorganOverweight
- 2026-06-02OppenheimerOutperform
Competitors — ulcerative colitis
- LLYELI LILLY & Co$1094.4B · D3
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- PFEPFIZER INC$142.2B · D3
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- SNYSanofi$52.5B · D1
- AAVXFAbivax S.A.$10.9B · D1
- PTGXProtagonist Therapeutics, Inc$8.6B · D0
- SYRESpyre Therapeutics, Inc.$8.5B · D6
- ANABANAPTYSBIO, INC$1.5B · D2
Recent news
- 2026-07-21ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
- 2026-07-09Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
- 2026-07-09Price to sales forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
- 2026-07-03Odyssey Therapeutics Inc (ODTX) Dividend News Alerts - DividendInvestor.com
- 2026-06-20Odyssey Therapeutics, Inc. (ODTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
- 2026-06-17ODTX: Strong clinical progress and IPO proceeds position the company for late-stage development - TradingView
- 2026-06-17Odyssey Therapeutics Reports Positive Phase 2a Proof-of-Concept Data for OD-001 in Ulcerative Colitis and Q1 2026 Financial Results - Quiver Quantitative
- 2026-06-17Odyssey Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(6.77) — 10-Q Summary - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.